Trial Profile

Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Methotrexate
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms SURPRISE

Most Recent Events

16 Jun 2018 Results (n=105) presented at the 19th Annual Congress of the European League Against Rheumatism.
31 May 2018 Primary endpoint (Changes over time in the number of patients maintaining discontinuation (maintenance rate) [ Time Frame: Week 52 to Week 104 ]) has not been met, as per the results published in the Annals of the Rheumatic Diseases
31 May 2018 Results published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com